R1626, pegylated interferon and ribavirin: The future multitherapy for hepatitis C?;R1626, interféron pégylé et ribavirine, la trithérapie de demain pour l'hépatite C?

Virologie

Volumn 12, Issue 5, 2008, Pages 386-387

  Boulestin, A ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4' AZIDOCYTIDINE; 4' AZIDOCYTIDINE 2',3',5' TRIISOBUTYRATE; ANTIVIRUS AGENT; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; DOSE RESPONSE; DRUG POTENTIATION; DRUG TOLERABILITY; GENE MUTATION; HEPATITIS C; HUMAN; MONOTHERAPY; NOTE;

HEPATITIS C VIRUS;

EID: 58649097237     PISSN: 12678694     EISSN: None     Source Type: Journal    
DOI: 10.1684/vir.2008.0191     Document Type: Note

References (2)

1. SK Roberts et al. Robust antiviral activity of R1626, a novel nucleoside analog : a randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology 2008 ; 48 : 398-406.
2. PJ Pockros et al. R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 2008 ; 48 : 385-397.